ICER Analysis Flags Pfizer’s ATTR-CM Therapy Vyndamax/Vyndaqel as Costly, Suggests Price Cut
The Institute for Clinical and Economic Review (ICER), a US-based non-profit organization specializing in drug...
Drug
Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...
Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...
Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...
Hansoh Pharmaceutical’s EGFR Inhibitor Ameile Files for Adjuvant Therapy Approval with NMPA
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading biopharmaceutical company based in China, has...
NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin
The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...
Apeiron Therapeutics Sells Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for USD 30 Million
Apeiron Therapeutics, a Shanghai-based biopharmaceutical company, has reached an agreement to sell all rights to...
Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA
Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...
J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure
Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...
Sino Biopharmaceutical Submits Market Approval Filing for CDK2/4/6 Inhibitor Culmerciclib in Breast Cancer
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced the submission...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...
China’s NMPA Suspends Daewoong Bio’s Cefodizime Over Inspection Refusal
The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...
Bain Capital-Backed Tenacia Wins NMPA Approval for Ganaxolone Oral Suspension for CDKL5 Deficiency
Tenacia, a central nervous system (CNS) specialist company incubated by Bain Capital, has announced that...
Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers
Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...
Consun Pharmaceutical Gets NMPA Go-Ahead for CKD Drug Clinical Trial
Consun Pharmaceutical Group Ltd (HKG: 1681), a leading Chinese pharmaceutical company, has announced that it...
Shanghai Ruijin Hospital’s Hainan Subsidiary Adopts ANI Pharmaceuticals’ Veregen for HPV Treatment
ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented...
Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...
Everest Medicines’ Nefecon Receives NMPA Review, Signaling Potential Treatment Milestone for IgAN Patients
Everest Medicines (HKG: 1952), a biopharmaceutical company dedicated to addressing critical medical needs in Asian...
Grand Pharmaceutical Gets Nod for Phase II Sepsis Study of STC3141 in China
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced that it has...
Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo (efgartigimod alfa SC) in gMG
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE (NASDAQ: ARGX)...